Shanghai Fosun Pharmaceutical (02196) has obtained approval from the China Securities Regulatory Commission to publicly issue corporate bonds to professional investors.

18:37 26/02/2026

Fosun Pharma (02196) announced that recently the company received the approval from the China Securities Regulatory Commission (CSRC) for Shanghai Fosun Pharma (Group) Co., Ltd. to publicly issue technology innovation corporate bonds to professional investors (CSRC Approval [2026] No. 298).

Shanghai Fosun Pharmaceutical (02196) announced that the company has recently received approval from the China Securities Regulatory Commission (CSRC) for the public issuance of technological innovation corporate bonds to professional investors. According to the approval, the CSRC has agreed to the company's application to publicly issue up to RMB 6 billion worth of technological innovation corporate bonds to professional investors. The approval is valid for 24 months from the date of registration, during which the company can issue the bonds in installments.

YIDU TECH (02158) repurchased nearly 2.3 million Hong Kong dollars on the 26th, accumulating more than 74 million Hong Kong dollars in repurchases within a month.

C FIN INT INV (00721) announces interim results with a net loss of HK$3.703 million, a year-on-year profit turning into a loss.

Green Energy GP (00979) releases its interim results with a shareholder loss of HK$4.965 million, a decrease of 31.19% compared to the same period last year.

YIDU TECH (02158) repurchased nearly 2.3 million Hong Kong dollars on the 26th, accumulating more than 74 million Hong Kong dollars in repurchases within a month.

C FIN INT INV (00721) announces interim results with a net loss of HK$3.703 million, a year-on-year profit turning into a loss.

Green Energy GP (00979) releases its interim results with a shareholder loss of HK$4.965 million, a decrease of 31.19% compared to the same period last year.